HC Wainwright Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its price target lifted by HC Wainwright from $400.00 to $425.00 in a research note released on Thursday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

UTHR has been the topic of several other reports. UBS Group upped their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Oppenheimer upped their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Jefferies Financial Group lifted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Finally, Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $366.43.

United Therapeutics Stock Performance

Shares of UTHR stock traded up $2.68 during mid-day trading on Thursday, reaching $376.65. The stock had a trading volume of 165,839 shares, compared to its average volume of 465,426. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $377.92. The firm has a market cap of $16.76 billion, a price-to-earnings ratio of 16.42, a PEG ratio of 1.31 and a beta of 0.57. The business’s fifty day moving average is $354.88 and its 200-day moving average is $315.69.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the firm posted $5.38 EPS. On average, research analysts forecast that United Therapeutics will post 24.75 earnings per share for the current year.

Insider Activity

In related news, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares in the company, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the transaction, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at $2,358,277.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 98,412 shares of company stock worth $33,971,508 over the last quarter. 11.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of UTHR. Meiji Yasuda Asset Management Co Ltd. increased its position in United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 33 shares during the last quarter. Toronto Dominion Bank increased its holdings in shares of United Therapeutics by 0.8% during the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after buying an additional 37 shares during the last quarter. ClariVest Asset Management LLC raised its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. grew its position in United Therapeutics by 1.8% in the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 48 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.